Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 27, 2015 9:58am

194 Views

Post# 23666875

RE:RE:RE:Chines deal secured....naysayers proved wrong yet again :)

tundup, thanks as always for your interpretation and insight...very helpful.

Here is my very simple and positively biased perspective.
This potential deal is a clear indication that at least some biotech companies are recognizing that this epigenetic drug called rvx-208 is being recognized for it's global blockbuster potential.

I do wonder a bit about the cost +10% a bit but is seems really good.

Cheers to all!
Toinv :)

Can you imagine the royalty flow just from these 3 countries (huge populations) as they begin applications beyond MACE!

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?